正确的药物、正确的患者、正确的时间：生物制剂在类风湿关节炎中的应用前景如何？
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
机构信息
Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, 1649-028, Lisboa, Portugal.
Department of Rheumatology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Av. Professor Egas Moniz, 1649-035, Lisboa, Portugal.
出版信息
Arthritis Res Ther. 2017 Oct 24;19(1):239. doi: 10.1186/s13075-017-1445-3.
Abstract
Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA). Investigation to identify predictive tools of bDMARD response is a highly active and prolific area of research. In addition to clinical phenotyping, cellular and molecular characterisation of synovial tissue and blood in patients with RA, using different technologies, can facilitate predictive testing. This narrative review will summarise the literature for the available bDMARD classes and focus on where progress has been made. We will also look ahead and consider the increasing use of 'omics' technologies, the potential they hold as well as the challenges, and what is needed in the future to fully realise our ambition of personalised bDMARD treatment.
摘要
个体化生物制剂（bDMARDs）以最大化疗效并提供安全有效的治疗是类风湿关节炎（RA）管理的关键目标。寻找预测 bDMARD 反应的工具是一个非常活跃和多产的研究领域。除了对 RA 患者的临床表型进行评估外，还可以使用不同的技术对滑膜组织和血液进行细胞和分子特征分析，从而促进预测性检测。本文综述了现有的 bDMARD 类药物的相关文献，并重点介绍了取得进展的领域。我们还将展望未来，考虑“组学”技术的广泛应用，以及它们作为潜在工具的优势和挑战，以及未来实现个体化 bDMARD 治疗目标所需的条件。
相似文献
1
Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?正确的药物、正确的患者、正确的时间：生物制剂在类风湿关节炎中的应用前景如何？
Arthritis Res Ther. 2017 Oct 24;19(1):239. doi: 10.1186/s13075-017-1445-3.
2
Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment: A pilot study.类风湿关节炎患者滑膜组织中白细胞介素 6 的产生与生物治疗的临床和影像学反应的相关性：一项初步研究。
PLoS One. 2018 May 22;13(5):e0197001. doi: 10.1371/journal.pone.0197001. eCollection 2018.
3
Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.类风湿关节炎中的生物难治性疾病：来自英国风湿病学会类风湿关节炎生物制剂注册处的结果。
Ann Rheum Dis. 2018 Oct;77(10):1405-1412. doi: 10.1136/annrheumdis-2018-213378. Epub 2018 Jul 6.
4
Distribution of Podoplanin in Synovial Tissues in Rheumatoid Arthritis Patients Using Biologic or Conventional Disease-Modifying Anti-Rheumatic Drugs.使用生物制剂或传统改善病情抗风湿药物的类风湿关节炎患者滑膜组织中血小板源性内皮细胞黏附分子-1的分布
Curr Rheumatol Rev. 2017;13(1):72-78. doi: 10.2174/1573397112666160331143607.
5
Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer.类风湿关节炎合并癌症患者的生物制剂类改善病情抗风湿药物的应用。
Clin Rheumatol. 2020 Mar;39(3):787-794. doi: 10.1007/s10067-019-04874-x. Epub 2019 Dec 18.
6
Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study.预测类风湿关节炎对三种生物制剂治疗反应的基线基因表达特征识别：一项回顾性观察研究。
Arthritis Res Ther. 2016 Jul 19;18:159. doi: 10.1186/s13075-016-1052-8.
7
Treatment of rheumatoid arthritis: Unraveling the conundrum.类风湿关节炎的治疗：揭开谜团。
J Autoimmun. 2015 Dec;65:1-18. doi: 10.1016/j.jaut.2015.10.003. Epub 2015 Oct 27.
8
Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.滑膜细胞和分子特征可对 csDMARD 治疗的临床反应进行分层，并预测早期类风湿关节炎患者的影像学进展。
Ann Rheum Dis. 2019 Jun;78(6):761-772. doi: 10.1136/annrheumdis-2018-214539. Epub 2019 Mar 16.
9
Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.患者特征会影响 RA 生物药物的选择，并且会使非 TNF 抑制剂生物药物看起来比 TNF 抑制剂生物药物更具危害性。
Ann Rheum Dis. 2018 May;77(5):650-657. doi: 10.1136/annrheumdis-2017-212395. Epub 2017 Dec 13.
10
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.阿达木单抗、依那西普、英夫利昔单抗、聚乙二醇化赛妥珠单抗、戈利木单抗、托珠单抗和阿巴西普用于治疗既往未使用改善病情抗风湿药物治疗且仅在传统改善病情抗风湿药物治疗失败后的类风湿关节炎：系统评价和经济学评估。
Health Technol Assess. 2016 Apr;20(35):1-610. doi: 10.3310/hta20350.
引用本文的文献
1
Programmable chronogenetic gene circuits for self-regulated circadian delivery of biologic drugs.用于生物药物自我调节昼夜节律递送的可编程生物钟基因电路。
J Control Release. 2025 Sep 10;385:113959. doi: 10.1016/j.jconrel.2025.113959. Epub 2025 Jun 18.
2
High-Titer Rheumatoid Factor is Associated with Worse Clinical Outcomes and Higher Needs for Advanced Therapies in Rheumatoid Arthritis Under Real-Life Conditions.在现实生活条件下，高滴度类风湿因子与类风湿关节炎更差的临床结局及对先进治疗的更高需求相关。
Rheumatol Ther. 2025 Feb;12(1):123-136. doi: 10.1007/s40744-024-00730-w. Epub 2024 Dec 19.
3
Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.类风湿关节炎患者中托珠单抗的真实世界使用及规则测试以预测治疗反应：RISE注册研究结果
Rheumatol Ther. 2023 Aug;10(4):1055-1072. doi: 10.1007/s40744-023-00568-8. Epub 2023 Jun 22.
4
Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? - A Cohort Study in a Colombian Population.托法替布在类风湿关节炎患者中常规治疗后的疗效是否优于生物治疗后的疗效？——一项针对哥伦比亚人群的队列研究。
Biologics. 2022 Jul 13;16:107-117. doi: 10.2147/BTT.S361164. eCollection 2022.
5
Expectations and educational needs of rheumatologists, rheumatology fellows and patients in the field of precision medicine in Canada, a quantitative cross-sectional and descriptive study.加拿大精准医学领域风湿病学家、风湿病专科住院医师和患者的期望与教育需求：一项定量横断面描述性研究
BMC Rheumatol. 2021 Nov 29;5(1):52. doi: 10.1186/s41927-021-00222-2.
6
Factors Determining Retreatment Time Interval of Rituximab in Korean Patients With Rheumatoid Arthritis.韩国类风湿关节炎患者中决定利妥昔单抗再治疗时间间隔的因素
Front Med (Lausanne). 2021 Oct 28;8:765535. doi: 10.3389/fmed.2021.765535. eCollection 2021.
7
Multi-omics approach to precision medicine for immune-mediated diseases.用于免疫介导疾病精准医学的多组学方法。
Inflamm Regen. 2021 Aug 1;41(1):23. doi: 10.1186/s41232-021-00173-8.
8
Berberine Delays Onset of Collagen-Induced Arthritis through T Cell Suppression.小檗碱通过抑制 T 细胞延迟胶原诱导性关节炎的发病。
Int J Mol Sci. 2021 Mar 29;22(7):3522. doi: 10.3390/ijms22073522.
9
Nutrition and Rheumatoid Arthritis in the 'Omics' Era.营养与“组学”时代的类风湿关节炎
Nutrients. 2021 Feb 26;13(3):763. doi: 10.3390/nu13030763.
10
JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis.JAK抑制剂与类风湿关节炎中B细胞免疫反应的调节
Front Med (Lausanne). 2021 Feb 5;7:607725. doi: 10.3389/fmed.2020.607725. eCollection 2020.
本文引用的文献
1
Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis.探索炎症代谢组学特征以预测类风湿关节炎患者对肿瘤坏死因子-α抑制剂的反应
PLoS One. 2016 Sep 15;11(9):e0163087. doi: 10.1371/journal.pone.0163087. eCollection 2016.
2
A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study.细胞生物标志物组合可预测类风湿关节炎患者对利妥昔单抗治疗无反应：一项为期24周的观察性研究。
Arthritis Res Ther. 2016 Aug 24;18(1):190. doi: 10.1186/s13075-016-1091-1.
3
Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?类风湿关节炎患者的基线血清微小RNA能否预测对肿瘤坏死因子-α抑制剂的反应？
Arthritis Res Ther. 2016 Aug 24;18(1):189. doi: 10.1186/s13075-016-1085-z.
4
Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis.众包评估常见遗传因素对预测类风湿关节炎对抗 TNF 治疗反应的作用。
Nat Commun. 2016 Aug 23;7:12460. doi: 10.1038/ncomms12460.
5
Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register.类风湿关节炎患者中预测肿瘤坏死因子-α抑制剂疼痛及早期停药的因素：来自英国风湿病学会生物制剂登记处的结果
BMC Musculoskelet Disord. 2016 Aug 12;17:337. doi: 10.1186/s12891-016-1192-7.
6
Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study.预测类风湿关节炎对三种生物制剂治疗反应的基线基因表达特征识别：一项回顾性观察研究。
Arthritis Res Ther. 2016 Jul 19;18:159. doi: 10.1186/s13075-016-1052-8.
7
Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.托珠单抗在生物制剂初治类风湿关节炎患者中达到临床和功能缓解及维持疗效的有效性和安全性：FIRST Bio 研究。
Mod Rheumatol. 2017 Mar;27(2):217-226. doi: 10.1080/14397595.2016.1206507. Epub 2016 Jul 14.
8
Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.钙卫蛋白和肿瘤坏死因子血清谷值水平可识别类风湿关节炎和银屑病关节炎缓解期或疾病活动度低的患者的能量多普勒超声滑膜炎。
Arthritis Res Ther. 2016 Jul 8;18(1):160. doi: 10.1186/s13075-016-1032-z.
9
Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity.网络分析确定了人类自身免疫中分泌ISG15的促炎浆细胞极化。
J Immunol. 2016 Aug 15;197(4):1447-59. doi: 10.4049/jimmunol.1600624. Epub 2016 Jun 29.
10
Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis.类风湿关节炎患者中托珠单抗反应的遗传和临床生物标志物
Pharmacol Res. 2016 Sep;111:264-271. doi: 10.1016/j.phrs.2016.06.016. Epub 2016 Jun 20.
Zotero 插件